Metrion Biosciences Overview
- Year Founded
-
2015

- Status
-
Private
- Employees
-
47

- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$4.06M
- Investors
-
7
Metrion Biosciences General Information
Description
Operator of a contract research organization intended to focus on delivering a range of preclinical drug discovery screening services. The company's platform provides highly skilled electrophysiology screening services in multiple formats for medicinal chemistry support, and also offers flexible business models according to the scope of each program, with both fee-for-service and collaborative options and options to access integrated drug discovery services, enabling clients with the support of medicinal chemistry optimization programs, compliant cardiac safety profiling assays, neuroscience assays, and translational assays.
Contact Information
Website
www.metrionbiosciences.comCorporate Office
- Building 2, Granta Centre, Great Abington
- First Floor
- Cambridge CB21 6AL
- England, United Kingdom
Corporate Office
- Building 2, Granta Centre, Great Abington
- First Floor
- Cambridge CB21 6AL
- England, United Kingdom
Metrion Biosciences Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
13. Later Stage VC | 20-Dec-2023 | $4.06M | Completed | Generating Revenue | ||
12. Later Stage VC (Series AAA) | 06-Apr-2021 | Completed | Generating Revenue | |||
11. Grant | 01-Oct-2020 | Completed | Generating Revenue | |||
10. Grant | 01-Jun-2020 | Completed | Generating Revenue | |||
9. Grant | 01-Jul-2019 | Completed | Generating Revenue | |||
8. Early Stage VC | 01-Apr-2019 | Completed | Generating Revenue | |||
7. Grant | 01-Sep-2018 | Completed | Generating Revenue | |||
6. Grant | 28-Aug-2018 | Completed | Generating Revenue | |||
5. Early Stage VC | 30-Apr-2018 | $1.34M | $1.34M | Completed | Generating Revenue | |
4. Grant | 01-Feb-2018 | $194K | Completed | Startup |
Metrion Biosciences Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
B PREFERENCE | ||||||||
B ORDINARY | ||||||||
2023 A PREFERENCE | ||||||||
Ordinary | ||||||||
Ordinary | ||||||||
A Preference | ||||||||
Ordinary | 106,663 | $0.010884 | $4.08 | $4.08 | 1x | $4.08 | 7.19% | |
Ordinary | 191,125 | $0.010884 | $5.44 | $5.44 | 1x | $5.44 | 12.89% |
Metrion Biosciences Comparisons
Industry
Financing
Details
Metrion Biosciences Competitors (31)
One of Metrion Biosciences’s 31 competitors is Sygnature Discovery, a Private Equity-Backed company based in Nottingham, United Kingdom.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Sygnature Discovery | Private Equity-Backed | Nottingham, United Kingdom | ||||
Shanghai Medicilon | Formerly VC-backed | Shanghai, China | ||||
Thousand Oaks Biopharmaceuticals | Venture Capital-Backed | Nantong, China | ||||
Sphere Fluidics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
Gyre Therapeutics | Formerly VC-backed | San Diego, CA |
Metrion Biosciences Patents
Metrion Biosciences Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
GB-201811165-D0 | Novel compounds | Inactive | 06-Jul-2018 | ||
US-20210275499-A1 | Heterocyclic sulfonamide derivatives and pharmaceutical uses thereof | Active | 06-Jul-2018 | ||
CA-3105757-A1 | Heterocyclic sulfonamide derivatives and pharmaceutical uses thereof | Pending | 06-Jul-2018 | ||
US-12128028-B2 | Heterocyclic sulfonamide derivatives and pharmaceutical uses thereof | Active | 06-Jul-2018 | ||
US-20250082609-A1 | Heterocyclic sulfonamide derivatives and pharmaceutical uses thereof | Pending | 06-Jul-2018 | A61K31/4164 |
Metrion Biosciences Signals
Metrion Biosciences Investors (7)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Maven Capital Partners (Glasgow) | PE/Buyout | Minority | ||
Gresham House | Asset Manager | Minority | ||
O2h Ventures | Venture Capital | Minority | ||
Biomedical Catalyst | Government | |||
SyndicateRoom | Venture Capital | Minority |
Metrion Biosciences FAQs
-
When was Metrion Biosciences founded?
Metrion Biosciences was founded in 2015.
-
Where is Metrion Biosciences headquartered?
Metrion Biosciences is headquartered in Cambridge, United Kingdom.
-
What is the size of Metrion Biosciences?
Metrion Biosciences has 47 total employees.
-
What industry is Metrion Biosciences in?
Metrion Biosciences’s primary industry is Drug Discovery.
-
Is Metrion Biosciences a private or public company?
Metrion Biosciences is a Private company.
-
What is the current valuation of Metrion Biosciences?
The current valuation of Metrion Biosciences is
. -
What is Metrion Biosciences’s current revenue?
The current revenue for Metrion Biosciences is
. -
How much funding has Metrion Biosciences raised over time?
Metrion Biosciences has raised $9.7M.
-
Who are Metrion Biosciences’s investors?
Maven Capital Partners (Glasgow), Gresham House, O2h Ventures, Biomedical Catalyst, and SyndicateRoom are 5 of 7 investors who have invested in Metrion Biosciences.
-
Who are Metrion Biosciences’s competitors?
Sygnature Discovery, Shanghai Medicilon, Thousand Oaks Biopharmaceuticals, Sphere Fluidics, and Gyre Therapeutics are some of the 31 competitors of Metrion Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »